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NaPi-IIb (Slc34a2) is a Na+-dependent phosphate transporter that accounts for the majority of 
active phosphate transport into intestinal epithelial cells. Its abundance is regulated by dietary 
phosphate, being high during dietary phosphate restriction. Intestinal ablation of NaPi-IIb in 
mice leads to increased fecal excretion of phosphate, which is compensated by enhanced renal 
reabsorption. Here we compared the adaptation to dietary phosphate of wild type (WT) and 
NaPi-IIb-/- mice. High phosphate diet (HPD) increased fecal and urinary excretion of 
phosphate in both groups, though NaPi-IIb-/- mice still showed higher fecal excretion and 
lower urinary excretion than WT. In both genotypes low dietary phosphate (LDP) resulted in 
reduced fecal excretion and almost undetectable urinary excretion of phosphate. Consistently, 
the expression of renal cotransporters after prolonged LDP was similar in both groups. Plasma 
phosphate levels declined more rapidly in NaPi-IIb-/- mice upon LDP, though both genotypes 
had comparable levels of 1,25(OH)2vitamin D3, parathyroid hormone and fibroblast growth 
factor 23. Instead, NaPi-IIb-/- mice fed LDP had exacerbated hypercalciuria, higher urinary 
excretion of corticosterone and deoxypyridinoline, together with lower bone mineral density 
and higher number of osteoclast. These data suggest that during dietary phosphate restriction 
NaPi-IIb-mediated intestinal phosphate absorption prevents excessive demineralization of 
bone as an alternative source of phosphate.    
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Introduction 
Phosphate (Pi) is vital for many biological functions including energy metabolism, 
intracellular signaling, structural composition of cellular membranes, and bone 
mineralization. Pi homeostasis is regulated by the coordinated interplay of different organs 
and endocrine networks. The intestine absorbs Pi from the diet and kidneys reabsorb Pi from 
the primary urine filtrate. Additionally, the bones serve as a reservoir for Pi, where it can be 
deposited as hydroxyapatite or released in case Pi supply is low1,2. Under normal conditions, 
osteoblastic bone formation is in balance with osteoclastic bone resorption. Several hormones 
such as parathyroid hormone (PTH) or glucocorticoids can stimulate osteoclast activity and 
thereby increase bone mineral release and promote demineralization3,4. 
The Slc34 family of Na+-dependent Pi transporters plays an essential role in Pi homeostasis. 
In the murine intestine, transcellular transport of Pi occurs mainly in the ileum, where NaPi-
IIb (Slc34a2) is localized5,6. NaPi-IIb seems to be the major murine intestinal Pi transporter, 
as its depletion results in abrogation of Na+-dependent transport of Pi and increased fecal loss 
of Pi7,8. Although mutations in NaPi-IIb have been described as a main cause of pulmonary 
alveolar microlithiasis in humans9, Pi metabolism in most of these patients has not been 
investigated. NaPi-IIa (Slc34a1) and NaPi-IIc (Slc34a3) are responsible for the renal 
reabsorption of Pi. Both transporters are localized in the brush border membrane (BBM) of 
the renal proximal tubular cells10,11. NaPi-IIa accounts for the majority of Pi reabsorption, 
since its ablation in mice leads to severe renal Pi wasting and hypophosphatemia, resulting in 
underdeveloped bone trabeculae, impaired bone formation and nephrocalcinosis in young 
mice12,13. Hypophosphatemia and nephrocalcinosis have been also reported in patients with 
mutations in NaPi-IIa14,15, and gene wide association studies indicate a strong correlation 
between NaPi-IIa and plasma levels of Pi16. In contrast, deletion of NaPi-IIc does not impair 
Pi homeostasis in mice17,18; however, many studies have reported mutations in NaPi-IIc in 
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patients with hereditary hypophosphatemic rickets with hypercalciuria (for review see19,20). 
The Slc20 family of Na+-dependent Pi transporters consists of Pit1 and Pit2, both showing 
broad tissue distribution including the epithelia of intestine and the renal proximal tubule21. 
Their contribution to intestinal and renal transport of Pi remains to be tested, though the renal 
expression of Pit2 is regulated by factors controlling Pi homeostasis22. 
The abundance of Slc34 transporters is regulated by a hormonal network consisting of PTH, 
fibroblast growth factor 23 (FGF23) and vitamin D3 (for review see23,24). PTH and FGF23 
target the kidney to promote phosphaturia by removing NaPi-IIa and NaPi-IIc from the BBM 
of proximal cells (for review see 25), whereas vitamin D3 acts on the intestine to stimulate 
absorption of Pi by increasing the expression of NaPi-IIb 26. In addition, each of these 
hormones controls the levels of the other two (for review see 23,24).  
The dietary Pi content influences the levels of Pi-regulating hormones and Pi-transporters. 
Thus, low dietary Pi as well as hypophosphatemia increase the abundance of NaPi-IIa, NaPi-
IIc and NaPi-IIb22,27-30 and thereby promote intestinal absorption and renal reabsorption. 
These changes are at least in part secondary to higher plasma levels of vitamin D3 and 
reduced concentrations of FGF23 and PTH28. However, studies in VDR deficient mice 
indicate that stimulation of NaPi-IIb also occurs in a vitamin D3 independent fashion29,30. The 
reduced levels of FGF23 and PTH triggered by hypophosphatemia remove the suppression of 
renal NaPi-IIa and NaPi-IIc and thereby enhance renal Pi reabsorption. In contrast, high 
dietary Pi as well as hyperphosphatemia  stimulate PTH and FGF23 and reduce vitamin 
D328,31,32. In addition to its phosphaturic effect, high FGF23 also reduces the production of 
vitamin D3 and increases its degradation33, blunting the stimulatory effect on intestinal Pi 
absorption. Besides their effects on Pi handling, vitamin D3 and PTH also control the levels of 
plasma Ca2+ by stimulating the expression of intestinal (TRPV6, calbindin D9K and Ca2+-
ATPase) and renal (TRPV5, calbindin D28K and NCX1) proteins involved in epithelial Ca2+ 
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transport (for review see34,35) as well as by stimulation of osteoclasts and thereby bone 
resorption36.  
As indicated above, intestinal ablation of NaPi-IIb in mice abolishes Na+-dependent Pi uptake 
into ileal BBM7,8. However, under standard dietary conditions these mice only show slightly 
increased fecal Pi loss, which is compensated by reduced urinary excretion, thus preserving 
normophosphatemia. Since the expression of NaPi-IIb is upregulated by low dietary Pi37, the 
role of NaPi-IIb may become more important once dietary Pi is restricted. In this study we 
compare the effect of the dietary Pi content, particularly Pi-restriction, in wild type (WT) and 
intestinal-specific NaPi-IIb deficient mice (NaPi-IIb-/-) and show that upon Pi-restriction 
NaPi-IIb-/- mice demineralize bone which may help to prevent more severe 
hypophosphatemia. 
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Results 
Intestinal ablation of NaPi-IIb and Pi deprivation causes transient hypophosphatemia 
and exacerbates urinary calcium excretion Urinary and stool samples from WT and NaPi-
IIb-/- mice were collected in metabolic cages under standard conditions as well as after 
adaptation to either high dietary Pi (HPD) for 3 days, or to low dietary Pi (LPD) for 3 or 14 
days (Figure 1). For both genotypes, the fecal excretion of Pi reflected the dietary Pi content: 
it was higher in animals fed high Pi and progressively lower in those fed low Pi as compared 
with mice kept on normal chow (Figure 1A). Except for the HPD, there was a tendency for 
increased fecal Pi excretion in NaPi-IIb-/- compared with WT mice, which was only 
significant during normal dietary conditions when absolute values were compared. However, 
the relative differences in fecal Pi excretion between both genotypes actually increased with 
decreasing levels of Pi in the diet: NaPi-IIb-/- showed around 13% higher excretion than WT 
mice when fed normal diet whereas the increase was 41% and 45% in the groups fed low Pi 
for 3 and 14 days, respectively (supplementary Figure 1).  
In both genotypes, the urinary excretion of Pi also adapted to the dietary Pi content, being 
higher in mice fed HPD diet and lower in the groups fed LPD as compared with mice 
receiving standard food (Figure 1B). NaPi-IIb-/- mice excreted significantly less Pi in urine 
than the WT littermates after 3 days of HPD adaptation. Pi excretion was almost undetectable 
after 3 or 14 days of LPD, and no differences between genotypes were observed.  
The different dietary conditions did not result in significant changes in plasma Pi values 
neither in WT nor in NaPi-IIb-/- mice (Figure 1C). However, due to a transient trend for 
hypophosphatemia in NaPi-IIb-/- fed LPD, plasma Pi was lower in mutant mice than in WT 
upon 3 days LPD. No differences between both genotypes were detected in the other dietary 
conditions.   
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The fecal excretion of Ca2+ was similar in both genotypes regardless of the feeding protocol, 
though there was a tendency for reduced excretion in animals fed on both experimental diets 
(Figure 1D). 
In both genotypes urinary Ca2+ excretion was comparable in mice fed a normal diet or HPD 
for 3 days, whereas a drastic increase was observed in animals fed a LPD for either 3 or 14 
days (Figure 1E). This increase was even stronger (more than 70%) in NaPi-IIb-/- compared to 
WT mice.  
Additionally a lower amount of creatinine was excreted in NaPi-IIb-/- mice after long term 
dietary Pi restriction (Table 1), but the creatinine clearance as an indicator for glomerular 
filtration rate (GFR) was not significantly altered, and excretion of other measured ions was 
comparable to WT littermates (Table 2). 
Plasma levels of Ca2+ progressively increased in the groups fed LPD compared with HPD 
(Figure 1F). However, there were no differences between WT and NaPi-IIb-/- mice under any 
dietary condition. 
Hormonal adaptation to dietary Pi is similar in both genotypes WT and NaPi-IIb-/- mice 
fed a LPD for 3 days showed higher levels of plasma 1,25-(OH)2 vitamin D3 compared to 
animals fed a HPD (Figure 2A). However, this difference was not observed in the groups fed 
LPD for 14 days. 1,25-(OH)2 vitamin D3 levels were similar in WT and NaPi-IIb-/- mice under 
all conditions. Renal mRNA expression of the vitamin D3 activating enzyme Cyp27b1 and 
protein abundance of the vitamin D3 catabolizing enzyme Cyp24a1 was analyzed in animals 
fed LPD for 14 days. There were no differences between WT and NaPi-IIb-/- mice neither on 
Cyp27b1 (Figure 2B), nor on Cyp24a1 (Figure 2C).   
The concentration of plasma PTH was significantly lower in animals fed a LPD for 3 days 
than in animals adapted to HPD (Figure 2D). Long term dietary Pi restriction led to a further 
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decrease in plasma PTH. However, WT and NaPi-IIb-/- mice showed similar PTH levels after 
adapting to the different dietary conditions. For intact FGF23 levels, a similar pattern to PTH 
was observed (Figure 2E), i.e. LPD resulted in a progressive reduction of plasma FGF23. No 
differences between genotypes were observed under the same conditions.  
Upon Pi restriction, Pi transport into renal BBMVs and expression of NaPi-IIa and 
NaPi-IIc is similar in both genotypes Transport studies were performed in renal BBMVs 
from mice fed LPD diet for 14 days. Uptakes were done in presence and absence of sodium, 
to determine sodium dependent and independent components of Pi, leucine and glucose 
transport. Uptakes of leucine and glucose were included as negative controls. Both WT and 
NaPi-IIb-/- mice showed at least a 97% decrease of Pi uptake into renal BBMVs in the absence 
of sodium, but the sodium dependent and independent transport rates were similar in both 
genotypes (Figure 3A). Transport rates of leucine (Figure 3B) and glucose (Figure 3C) also 
showed a strong dependency on sodium (more than 80%), and were similar in both groups of 
mice.  
The protein abundance of NaPi-IIa and NaPi-IIc was assessed in the same renal BBMV 
preparations that were used for the uptake experiments (long term dietary Pi restriction). In 
agreement with the urinary Pi and renal Pi-transport data, upon prolonged dietary Pi 
restriction, the expression of NaPi-IIa (Figure 3D) and NaPi-IIc (Figure 3E) were similar in 
WT and NaPi-IIb-/- mice.  
As expected and previously published37, NaPi-IIb protein abundance in ileum of WT mice 
was increased after 3 and 14 days of LPD compared to HPD, whereas the cotransporter was 
not detected in NaPi-IIb-/- animals (Figure 3F) 
Upon Pi restriction, the expression of proteins involved in renal calcium handling is 
comparable in both genotypes The abundance of proteins involved in renal Ca2+ handling 
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was assessed in WT and NaPi-IIb-/- animals after 14 days dietary Pi restriction. The 
expression of the Ca2+ channel TRPV5 was analyzed in apical membranes (Figure 4A), 
whereas the abundance of the Ca2+ sensing receptor (CaSR, Figure 4B) and calbindin-D28k 
(Figure 4C) was quantified in renal homogenates. Similar levels of all three proteins were 
observed in WT and NaPi-IIb-/- animals. 
Urinary excretion of deoxypyridinoline and corticosterone, bone mineral density and 
osteoclast number are altered in Pi-restricted NaPi-IIb-/- mice  Urinary excretion of 
deoxypyridinoline (DPD) was quantified as a marker for bone resorption (Figure 5A). The 
dietary content of Pi did not influence the urinary concentration of DPD in WT animals; 
however, LPD triggered a progressive increase in the amount of DPD excreted into urine by 
intestinal NaPi-IIb-/- mice. No difference was observed between WT and NaPi-IIb-/- fed a 
HPD or LPD for three days, whereas  after long term Pi restriction the levels of DPD in the 
urine of NaPi-IIb-/- animals were significantly higher (about 85%) than in the corresponding 
WT animals.  
Urinary corticosterone levels were similar in both genotypes under normal dietary conditions 
but were elevated in NaPi-IIb-/- mice compared to WT litter mates after 14 days of dietary Pi 
restriction (Figure 5B). The corticosterone metabolites 11-dehydrocorticosterone and 5α-
dihydrocorticosterone were also increased in NaPi-IIb-/- animals (113.2±19.9 and 176.2±14.8, 
respectively) compared to WT (52.0±10.4 and 109.0±15.5, respectively) after 14 days LPD. 
Bone mineral density (BMD) was measured in femurs of WT and NaPi-IIb-/- mice under 
normal dietary conditions as well as after 14 days LPD. Cortical BMD was elevated in NaPi-
IIb-/- compared to WT under standard diet conditions, whereas trabecular BMD was similar in 
both groups (Figures 5C and D). Cortical BMD was significantly reduced in NaPi-IIb-/- mice 
after dietary Pi restriction, whereas it remained unchanged in WT animals. Trabecular BMD 
was reduced in NaPi-IIb-/- mice when challenged with long term dietary Pi restriction, 
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compared with the WT littermates (Figures 5C and D). The number of osteoclasts lining the 
bony trabeculae in the distal femoral metaphysis of WT and NaPi-IIb-/- mice under normal 
dietary conditions, as well as after 14 days LPD, was assessed using immunohistochemistry 
for cathepsin K. While the number of osteoclasts expressing cathepsin K was comparable 
between WT and NaPi-IIb-/- mice under standard diet conditions (Figure 5E), the latter 
exhibited higher osteoclast counts after Pi dietary restriction compared to 14 day-Pi-restricted 
WT littermates (Figures 5E and 5F). 
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Discussion 
NaPi-IIb is considered to be the major apical Pi transporter in the small intestine since its 
intestinal ablation in mice abolishes Na+-dependent uptake of Pi into intestinal sacks and 
BBMV from ileum7,8, indicating the loss of active transcellular transport of Pi in the small 
intestine. However, under standard feeding conditions the absence of NaPi-IIb only leads to a 
moderate fecal wasting of Pi, which is compensated by increased renal reabsorption, thus 
resulting in normal plasma Pi. This mild phenotype suggests an alternative transport pathway 
across the intestinal epithelium able to supply enough Pi, at least under normal dietary Pi. 
Passive absorption through the paracellular pathway may contribute to this process when a 
sufficient gradient of Pi is established across the epithelium. However, in response to low 
dietary Pi the expression of NaPi-IIb increases27,28, indicating that the active component may 
be required to adapt to a reduced oral supply of Pi. Therefore, here we investigated whether 
the contribution of NaPi-IIb becomes higher once dietary Pi is limited.  
As observed in WT animals, the fecal excretion of Pi in NaPi-IIb-/- also increased with HPD 
and decreased under LPD. However, under all dietary conditions, the fecal Pi output was 
higher in NaPi-IIb-/- than WT, though the difference between genotypes was significant only 
in HPD when ANOVA was applied to the absolute values. The large differences in the fecal 
Pi content between the HPD and LPD groups may have masked the relatively smaller 
differences between genotypes in the normal and LPD; indeed, significant differences were 
observed in all feeding protocols when the excretion of NaPi-IIb-/- mice was normalized to the 
excretion of the dietary-matched WT. Moreover, normalization also indicated that the absence 
of NaPi-IIb had a larger impact in the Pi-restricted groups than in animals fed high Pi. This 
may indicate that the contribution of the active transport component (mediated mostly by 
NaPi-IIb) becomes bigger when dietary Pi is low: dietary restriction could theoretically result 
in lower Pi levels in the intestinal lumen, thus providing a lower gradient for passive transport 
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of Pi across the epithelium. As expected, 1,25-(OH)2 vitamin D3, a major stimulus for 
intestinal Pi absorption26, was increased in animals fed the LPD compared to HPD. However, 
no differences were detected between NaPi-IIb-/- and WT mice. This observation was further 
supported by the finding that the expression of Cyp27b1 and Cyp24a1 (mRNA and protein, 
respectively) was similar in both groups of mice. These renal enzymes are crucial in 
controlling the systemic levels of 1,25-(OH)2 vitamin D3, since Cyp27b1 converts 25(OH)D3 
into the active 1,25(OH)2D3, whereas Cyp24a1 catabolizes 1,25-(OH)2 vitamin D338. The 
higher NaPi-IIb abundance triggered by low dietary Pi/high 1,25-(OH)2 vitamin D3 might 
further increase the relative difference in Pi transport between WT and NaPi-IIb-/- animals, 
which is in agreement with the observed trend of higher relative differences in Pi excretion as 
dietary Pi is restricted.  
Dietary loading with Pi triggers a phosphaturic response whereas urinary Pi is low upon 
dietary Pi restriction. These changes inversely correlate with the abundance of the renal 
transporters NaPi-IIa and NaPi-IIc, which in turn are controlled by the plasma levels of PTH, 
FGF23, and 1,25(OH)2 vitamin D3. Thus, dietary supply of Pi increases the abundance of both 
hormones whereas Pi deficiency reduces their levels28,32. Similarly to the fecal output, also the 
urinary excretion of Pi adapted in a similar fashion in NaPi-IIb-/- and WT mice, increasing in 
response to HDP and decreasing upon dietary Pi restriction. Although the increase in renal Pi 
excretion triggered by the HPD was lower in NaPi-IIb-/- compared to the WT mice, the 
massive phosphaturia also observed in NaPi-IIb-/- mice indicates that the component 
responsible for the passive intestinal transport of Pi is able to absorb a considerable amount of 
Pi which must be later excreted by the kidney. Instead, both genotypes excreted similarly low 
amounts of Pi after adaptation to LPD. Since WT animals fed low Pi already increased renal 
Pi reabsorption to a point where almost no Pi is excreted with urine (especially after 14 days 
LPD), it is not surprising that the kidneys of NaPi-IIb-/- mice cannot further compensate for 
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the impaired intestinal absorption.  In agreement with this maximal and similar reduction of 
urinary Pi excretion the levels of PTH and FGF23, both phosphaturic hormones, were 
strongly and similarly reduced in WT and NaPi-IIb-/- mice fed LPD. Furthermore, transport of 
Pi into renal BBMV and protein expression of NaPi-IIa and NaPi-IIc was also similar in WT 
and NaPi-IIb-/- mice fed LPD during 14 days. The combination of increased fecal loss but 
similar (low) urinary excretion of Pi detected in NaPi-IIb-/- on LPD likely caused the more 
pronounced reduction in plasma Pi levels in NaPi-IIb-/- animals after 3 days of LPD. In 
contrast, WT mice were able to maintain normal Pi values though a tendency for reduced 
plasma Pi was detected after 14 days of LPD. The pronounced and earlier fall in plasma Pi 
may indicate that NaPi-IIb-/- animals need an extra-renal compensatory mechanism when 
facing longer Pi restriction and that this mechanism is activated within a few days after the 
onset of Pi depletion. 
Chronic hypophosphatemia may lead to osteomalacia and hypophosphatemic rickets39, due to 
the mobilization of Pi from bone and/or decreased mineralization of newly formed bone. The 
stronger increase in urinary Ca2+ excretion in the NaPi-IIb-/- mice during LPD suggested bones 
as source for Pi: although a drastic increase of urinary Ca2+ was observed in both genotypes 
when fed a LPD (both 3 and 14 days), urinary Ca2+ levels were more than 70% higher in 
NaPi-IIb-/- mice than in their WT littermates. High 1,25(OH)2 vitamin D3 stimulates not only 
Pi but also Ca2+ absorption in the intestine40, and therefore it may contribute to the increase in 
plasma and urinary Ca2+ observed in both animal groups with prolonged Pi deprivation. 
Moreover, intestinal Ca2+ absorption may be enhanced by the absence of Pi reacting with free 
Ca2+ in the intestinal lumen. In addition, low PTH may lead to urinary wasting of Ca2+, as a 
main function of this hormone is to promote Ca2+ reabsorption in the kidney41,42. However, 
none of these factors can explain the difference in urinary Ca2+ between WT and NaPi-IIb-/- 
mice, since they were equally affected in both genotypes. Moreover, the renal expression of 
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several proteins involved in Ca2+ transport, including TRPV5, calbindin-28K and the CaSR, 
was also similar in WT and NaPi-IIb-/- mice. Thus, in response to hypophosphatemia, bone 
resorption may be enhanced in NaPi-IIb-/- mice releasing Pi, together with Ca2+, at the cost of 
bone mass loss. In turn, renal excretion of Ca2+ will be higher to remove excessive Ca2+. This 
interpretation is further supported by the changes in urinary excretion of DPD, a marker for 
bone resorption43. DPD excretion was massively elevated in NaPi-IIb-/- mice upon prolonged 
Pi restriction, whereas no indication for enhanced bone resorption was detected in dietary-
matched WT. In agreement with the DPD data, BMD was decreased in Pi-restricted NaPi-IIb-
/- mice.  
NaPi-IIb-/- mice fed low Pi also showed higher urinary corticosterone, which is accepted to 
reflect its circulating levels. Glucocorticoids reduce bone formation rates44 and increase 
osteoclast number, promoting bone resorption45. The increase in glucocorticoids might 
partially explain the reduced bone mineralization as well as the increased osteoclast number 
observed in NaPi-IIb-/- deficient animals. Together, these observations strongly suggest that 
the compensation for the loss of active intestinal absorption of Pi requires the mobilization of 
Pi from bones when the dietary supply is low.   
In summary, we found that in response to dietary Pi restriction, renal compensation is not 
sufficient to maintain plasma Pi levels in mice lacking intestinal NaPi-IIb. Instead, and unlike 
to WT mice, NaPi-IIb-/- develop a transient hypophosphatemia followed by a compensatory 
mechanism that involves release of Pi from bone and may be mediated by glucocorticoids. 
Thus, active intestinal Pi absorption mediated by NaPi-IIb is critical to protect bone during 
periods of low dietary Pi availability.  
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Methods 
Animal handling Experiments were performed in two months old floxed-Slc34a2 male mice 
expressing villin-driven Cre recombinase (NaPi-IIb-/-) and their wild type litter mates (WT), 
generated as already described in detail8. Until reaching the indicated age, all mice were 
housed in single ventilated cages in an optimal hygienic husbandry facility. At the beginning 
of the experiment, mice were transferred to individual metabolic cages (Tecniplast, 
Buguggiate, Italy) and fed standard diets (0.8 % Pi, 1 % calcium), to collect basal urinary 
(under mineral oil) and stool samples. Then, animals were randomized in three groups: two of 
them received either a low (LPD; 0.1 % Pi, 1 % calcium) or high (HPD; 1.2 % Pi, 1 % 
calcium) Pi diet (Kliba Promivi AG, Switzerland) for 3 days, whereas the third group was fed 
the LPD for 14 days. Each of the 6 final experimental groups consisted of 10 animals. During 
the whole procedure mice were fed ad libitum with free access to water. Three days before 
harvesting samples, animals were placed again in metabolic cages to collect urine and stool. 
Mice were then anesthetized using ketamine and xylazine. Upon opening the abdominal 
cavity, blood was collected from the vena cava and centrifuged at 4°C in heparinized tubes for 
7 minutes at 7000 rpm. Plasma, organs and scrapings from mucosa of ileum were snap frozen 
in liquid nitrogen and stored at -80°C for further analysis. Urine was centrifuged at 10000 rpm 
for 10 minutes and stored at -20°C. Experiments were approved by the local veterinary 
authority (Veterinäramt Zürich) and performed according to Swiss Animal Welfare laws. 
Plasma, urine and stool parameters The levels of Pi in stool, urine and plasma were 
colorimetrically determined according to the Fiske Subbarow method46. For determination of 
fecal Pi content, dried stool was first dissolved in 0.6 M HCl for three days, homogenized and 
centrifuged as reported7. The Jaffe method was used to measure urinary creatinine47. Urinary 
calcium, sodium, potassium, magnesium and chloride as well as plasma calcium and 
creatinine were measured on a UniCel DxC 800 Synchron Clinical System (Beckman 
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Coulter), a service provided by the Zürich Integrative Rodent Physiology (ZIRP) facility. 
Calcium in stool was quantified using the QuantiChrom Calcium assay kit (Bio-Assay 
Systems). 
FGF23, PTH, vitamin D and deoxypyridinoline measurement The levels of intact FGF23 
and PTH in plasma were analyzed by ELISA (Immunotopics International, San Clemente, 
CA, USA), whereas plasma 1,25 (OH)2-Vitamin D3 was quantified by radioimmunoassay 
(Immunodiagnostic System, Frankfurt am Main, Germany). Urinary deoxypyridinoline (DPD) 
was assessed with an enzymatic immunoassay kit (MicroVue DPD EIA, Quidel Corporation, 
Athens, USA). All assays were performed according to the manufacturers’ protocol. 
Renal brush border membrane vesicle and homogenate preparation Brush border 
membrane vesicles (BBMV) were prepared from frozen kidneys as described before48. A 
polytron (PT 10-35, Kinematica GmbH, Lucerne) was used to homogenize kidneys in a buffer 
containing (in mM) 300 mannitol, 5 EGTA, 12 Tris-HCl (pH 7.1) and complete mini protease 
inhibitor cocktail (Roche, Switzerland). An aliquot of the homogenate was frozen and stored 
at -80°C for western blot analysis. Upon addition of MgCl2 (12 mM final concentration), the 
remaining homogenate was kept on ice for 15 minutes followed by centrifugation at 4500 rpm 
for 15 minutes at 4°C. The resulting supernatant was further centrifuged at 17500 rpm for 30 
minutes at 4°C to collect BBMV. The pellet, containing BBMV was resuspended in a buffer 
consisting of (in mM) 300 mannitol and 20 HEPES-Tris, pH 7.4.  
Uptake of 32P-phosphate, 3H-D-glucose and 14C-isoleucine into renal BBMV Uptakes 
were done according to the reported filtration technique49. Freshly prepared BBMV were 
incubated in solutions containing either 100 mM NaCl or 100 mM KCl, both solutions 
supplemented with 0.1 mM Pi and 32P as tracer.  3H-D-glucose and 14C-leucine uptakes were 
measured following the same protocol using solutions containing 0.1 mM D-glucose and 0.1 
mM isoleucine together with the indicated radiolabeled tracers. Uptakes were left to proceed 
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for either 30 seconds (3H-Glucose and 14C-leucine) or 1 minute (32P). The incorporation of 
tracers into the BBMV was measured with a β-counter (Packard BioScience). Remaining 
BBMVs were snap-frozen and stored at -80°C for western blot analysis. 
Total membrane fractions from ileum Scrapings from mucosa of ileum were homogenized 
in a buffer containing (in mM) 200 mannitol, 80 HEPES, 41 KOH and protease inhibitors, pH 
7.5. Homogenization was performed with MagNa Lyser Green Beads (Roche), in a Precellys 
24 Homogenizer. Upon centrifugation at 800 rpm for 20 minutes at 4°C, supernatants were 
further centrifuged at 41,000 rpm for 30 minutes at 4°C, and pellets containing total 
membrane proteins were resuspended in the same buffer used for homogenization. 
Western blot A Bio Rad DC protein assay kit (BioRad, Cressier, Switzerland) was first used 
to measure the protein concentration of renal homogenates and BBMV as well as of total 
membrane fractions from ileum. Then, 20 µg of proteins were mixed with Laemmli sample 
buffer, loaded on 9% or 12% acrylamide SDS-PAGE, and transferred onto polyvinylidene 
difluoride (PVDF) membranes (Immobilon-P, Millipore, Schaffhausen, Switzerland). Tris 
buffered saline (TBS) containing 5% fat free powder milk was used to block membranes for 
30 minutes at room temperature prior incubation overnight at 4°C with primary antibodies 
against NaPi-IIa10, NaPi-IIb6, NaPi-IIc50, TRPV551, CaSR (Thermofisher Scientific), 
Calbindin D28k (SWANT, Marly, Switzerland), Cyp24a1 (Protein Tech, Manchester, United 
Kingdom), and β-actin (Sigma-Aldrich, Buchs, Switzerland). Upon 3 washes with TBS, 
membranes were again blocked and incubated for 2 hours at room temperature with the 
appropriate (anti-mouse or anti-rabbit) secondary antibody linked to horseradish peroxidase 
(HRP) (Promega AG, Dübendorf, Switzerland). After 3 washes with TBS, membranes were 
exposed to HRP substrate (Western Chemiluminescence HRP Substrate, Millipore, 
Schaffhausen, Switzerland) for 5 minutes. Chemiluminiscence was detected with a LAS-4000 
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camera system (Fujifilm). Densitometric analysis was performed using ImageJ and the 
density of the proteins of interest was normalized to β-actin. 
Semi-quantitative real time RT-PCR Half a kidney was homogenized in RLT buffer 
supplemented with β-mercaptoethanol. RNA from homogenates was isolated using the 
Qiagen RNeasy Mini kit (Qiagen, Hombrechtikon, Switzerland) following the protocol 
provided by the supplier. TaqMan Reverse Transcription Kit (Applied Biosystems, Zug, 
Switzerland) was then used for reverse transcription of the isolated RNA according to the 
manufacturers’ protocol. To quantify relative gene expression, specific sets of primers and 
FAM/TAMRA-labelled probes for Cyp27b1 (Mm01165918_g1,) and Slc34a2 (Microsynth, 
Switzerland) were used, and their abundance was normalized to the expression of 
hypoxanthine-guanine phosphoribosyltransferase (HPRT, Microsynth, Switzerland). KAPA 
PROBE FAST qPCR Kit Master Mix (KAPA BIOSYSTEMS, Boston USA) containing 
primers (5 µM) and probe (25 µM) was used to amplify cDNA in a 7500 Fast Real Time PCR 
System (Applied Biosystems, Zug, Switzerland).  The cycle number at a given threshold (Ct) 
was measured and gene expression relative to the expression of HPRT was calculated 
according to the formula R=2^(CtHPRT-Ctgene of interest). 
Glucocorticoids Urinary glucocorticoids were quantified as described in the supplemental 
information. Full description of the method validation will be published elsewhere. Briefly, to 
each urine sample (500 μL) internal standards (corticosterone-D8 and creatinine-D3,100 
µg/mL) were added and samples were diluted to a final volume of 1.9 mL with sodium 
acetate buffer (100 mM, pH 4.3).  For de-conjugation ß-Glucuronidase (10000 units/mL) was 
added and samples were incubated in a thermoshaker thorough shaking (2 hours, 900 rpm, 55 
°C).  Samples were centrifuged (10 min, 16,000 × rcf, 4 °C) and supernatants (1800 µL) were 
used for solid phase extraction (SPE) on Oasis HBL SPE columns. Samples were eluted with 
methanol (3x 500 µL), followed by evaporation to dryness and reconstitution in methanol (25 
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µL, 10 min, 1300 rpm, 4 °C, thermoshaker). The urinary steroids were separated and 
quantified by ultra-pressure LC-MS/MS (UPLC-MS/MS) using an Agilent 1290 UPLC 
coupled to an Agilent 6490 triple quadrupole mass spectrometer equipped with a jet-stream 
electrospray ionization interface (Agilent Technologies, Santa Clara, CA, USA). Analyte 
separation was achieved using a reverse-phase column (1.7 μm, 2.1 × 150 mm; Acquity 
UPLC BEH C18; Waters). Masshunter software (Agilent Technologies) was used for data 
acquisition and analysis. 
Micro Computer Tomography Freshly isolated femurs were scanned in a Quantum GX 
microCT Imaging System (PerkinElmer) provided by the ZIRP facility. Distal epiphysis and 
subsequent diaphysis were imaged for 3 minutes using a 5 mm field of view at a tube current 
of 100 µA and 90 kV tube voltage. Analyze 12.0 program (AnalyzeDirect, Inc., Overland 
Park, USA) was used to asses bone mineral density (BMD) and bone volume data. Bones 
were analyzed from the end of the patellar surface of the distal epiphysis and 100 sections into 
the diaphysis were averaged. Grey scales of the scans were translated into BMD using a 
calibration curve obtained by scans of a 1200 mg/cm3 hydroxyapatite phantom (Micro-CT 
HA Phantom, QRM GmbH, Moehrendorf, Germany). 
Histomorphometric analysis Femoral bones stored in 98 % ethanol were washed and 
decalcified in 10% ethylenediamine tetraacetic acid over a period of 28 days. The bones were 
trimmed longitudinally, dehydrated through graded alcohols and routinely paraffin wax 
embedded. Sections (3-5 µm) were cut from the centers of the femurs, mounted on glass 
slides, deparaffinised in xylene, rehydrated through graded alcohols and stained with 
hematoxylin and eosin (HE) or subjected to cathepsin K immunohistochemistry (IHC), using 
standard protocols. IHC was performed using a rabbit anti-cathepsin K antibody (Abcam, 
United Kingdom). Briefly, sections were deparaffinised in xylene (2 × 5 min) and rehydrated 
in decreasing concentrations of ethanol (2 × 3 min washes in 100% ethanol, followed by 1 × 3 
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min wash in 96% ethanol). Sections underwent antigen retrieval by incubation with 10 mM 
citrate buffer at pH 6.0. Slides were then incubated for 1 h at 37°C with the primary antisera 
(1:200, diluted in Dako antibody diluent, Dako-Agilent Technologies, Denmark), followed by 
incubation for 30 min with a horse radish peroxidase (HRP)-labeled polymer, conjugated to a 
secondary anti-rabbit antibody (Dako EnvisionTM System, Dako-Agilent Technologies). The 
reaction was visualized using 3-amino-9-ethylcarbazole (AEC) as chromogen for 10 min, 
followed by light counterstain with hematoxylin, rinsing for 5 min in tap water and 
dehydration in ascending alcohols, clearing in xylene, coverslipping and mounting. All 
immunohistological stains were performed using an Autostainer (Dako Autostainer Universal 
Staining System Model LV-1, Dako-Agilent Technologies). 
All slides were scanned using a digital slide scanner (NanoZoomer-XR C12000; Hamamatsu, 
Japan), and the number of cathepsin K-labelled trabecular osteoclasts was calculated in the 
digital slides using the Visiopharm Integrator System (VIS, version 4.5.1.324, Visiopharm, 
Hørsholm, Denmark). Briefly, five circular regions of interest (ROI) with a radius of 100 μm 
were randomly selected in each bone in a blinded fashion. The regions of interest were placed 
in the primary spongiosa beneath the growth plate, excluding the cortical bone (modified 
from52). A threshold classification allowed recognition of positive (red-brown) multinucleated 
cells in each ROI, and the results were expressed as number of positive cells per 100 μm.  
Statistical Analysis Unpaired student’s t-test or ANOVA with Bonferroni correction for 
multiple comparisons were used to analyze comparisons. P-values < 0.05 were considered as 
significant. Data is presented as Mean + SEM. 
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Figure 1:  Intestinal ablation of NaPi-IIb and Pi deprivation causes transient 
hypophosphatemia and stimulates urinary calcium excretion. Fecal (A), urinary (B) and 
plasma (C) concentrations of Pi as well as fecal (D), urinary (E) and plasma (F) levels of Ca2+ 
were measured in samples collected from wild type (WT) and NaPi-IIb-/- mice (KO). Mice 
were fed diets containing normal (N), high (H) or low (L) amounts of Pi. The high Pi diet was 
provided for 3 days (3d) whereas the low Pi diet was provided for 3 (3d) and 14 days (14d), 
respectively.  Data is presented as mean + SEM (n=10) and was analyzed by ANOVA-
Bonferroni. Significant differences are indicated as: a/* p<0.05, b/** p<0.01 and 
c/***p<0.001, where letters indicate significant changes versus normal diets (or versus the 
high Pi diet, if normal diet is not available), and asterisks mark differences between genotypes 
under the same dietary condition. 
Figure 2: Hormonal adaptation to dietary Pi is similar in both genotypes. Circulating 
levels of 1,25-(OH)2 vitamin D3 (A), PTH (D) and intact FGF23 (E) were measured in plasma 
collected from wild type (WT) and NaPi-IIb-/- mice (KO) fed diets containing high (H) or low 
(L) amounts of Pi. The high Pi diet was provided for 3 days (3d) whereas the low Pi diet was 
provided for 3 (3d) and 14 days (14d). Renal mRNA levels of Cyp27b1 (B) and renal protein 
abundance of Cyp24a1 (C) were measured after 14 days of Pi restriction. Data is presented as 
mean + SEM (n=10), and was analyzed by ANOVA-Bonferroni. Significant differences are 
indicated as: a p<0.05, b p<0.01 and c p<0.001, were significances refer to high dietary Pi 
groups (no differences between genotypes were observed). 
Figure 3: Upon Pi restriction, Pi transport into renal BBMVs and expression of NaPi-IIa 
and NaPi-IIc is similar in both genotypes. Uptakes of Pi (A), leucine (B) and glucose (C) 
were performed with renal BBMVs isolated from wild type (WT) and NaPi-IIb-/- mice (KO) 
after 14 days of dietary Pi restriction (n=10). Experiments were carried out in the presence 
(Na) and absence (K) of Na+. The renal expression of NaPi-IIa (D) and NaPi-IIc (E) was 
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quantified by Western blot of the same BBMV used for the uptake experiments; the bar 
graphs show the corresponding densitometric analysis normalized for the expression of β-
actin (n=10). The abundance of NaPi-IIb in ileum (F) was quantified by Western blot in 
samples from wild type mice (WT) fed 3 days high (H) or low Pi (L) diets as well as 14 days 
low Pi (n=7); one sample of a corresponding dietary-matched NaPi-IIb-/- mice (KO) was also 
included; the bar graph show the densitometric analysis normalized for the expression of β-
actin. Uptakes and densitometry values are shown as mean + SEM. Differences between 
genotypes were analyzed by unpaired t-test (A-E), whereas differences versus the high dietary 
group were analyzed by ANOVA-Bonferroni (F). Significant differences are indicated as * 
p<0.05 and ** p<0.01. 
Figure 4: Upon Pi restriction, the expression of proteins involved in renal calcium 
handling is similar in both genotypes. Renal protein abundance of Cabindin 28K (A), 
TRPV5 (B) and calcium sensing receptor (C) was assessed by Western blot in homogenates 
(A, C) or BBM (B) from kidneys of wild type (WT) and NaPi-IIb-/- animals (KO) after 14 
days of Pi restriction. Corresponding densitometric analysis was normalized by the expression 
level of β-actin and data is shown as mean + SEM (n=10). Differences between genotypes 
were analyzed by unpaired t-test. 
Figure 5: Urinary excretion of deoxypyridinoline (DPD) and corticosterone as well as 
bone mineral density (BMD) and osteoclast number per tissue area are altered in Pi-
restricted NaPi-IIb-/- mice. Urinary DPD (A) levels were measured in samples from wild 
type (WT) and NaPi-IIb-/- mice (KO) mice fed 3 days high (H) or low (L) Pi diets as well as 
14 days low Pi. Corticosterone levels in urine (B) were determined in samples from mice fed 
normal diet (N) as well as after 14 days of Pi restriction (L). Cortical (C) and trabecular (D) 
BMD were measured in femurs of mice fed normal diet (N) as well as after 14 days Pi 
restriction. Numbers of osteoclasts expressing cathepsin K were assessed in the primary 
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spongiosa of wild type (WT) and NaPi-IIb-/- mice (KO) under normal dietary conditions (N) 
as well as after 14 day low Pi intake and expressed as average number of cells per 100 μm2 
(E). Representative pictures of cathepsin K-decorated osteoclasts (red-brown reaction, 
arrowheads) in the metaphysis of wild type and NaPi-IIb-/- mice after 14 days of Pi restriction 
are shown in panel F. Data is presented as mean + SEM (n≥7) significance was analyzed by 
ANOVA-Bonferroni. Significant differences are indicated as: a/* p<0.05, b/** p<0.01 and 
c/*** p<0.001, where letters represent the difference versus the corresponding high dietary 
group, whereas asterisks mark differences between genotypes under the same dietary 
conditions. 
Table 1: Metabolic data. Additional parameters measured in wild type (WT) and NaPi-IIb-/- 
mice (KO) fed diets containing normal (N), high (H) and low (L) amounts of Pi. The high Pi 
diet was provided for 3 days (3d) whereas the low Pi diet was provided for 3 (3d) and 14 days 
(14d).  Data is presented as mean + SEM (n≥10) and was analyzed by ANOVA-Bonferroni. 
Significant differences are indicated as: a/* p<0.05, b/** p<0.01 and c/***p<0.001, where 
letters indicate significant changes versus normal diets (or versus the high Pi diet, if normal 
diet is not available), and asterisks mark differences between genotypes under the same 
dietary condition.  
Table 2: Additional urinary parameters measured in samples collected from wild type 
(WT) and NaPi-IIb-/- mice (KO) after 14 days Pi restriction. Data is presented as mean + 
SEM (n≥10) and was analyzed by unpaired t-test. 
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Quantification of steroids and creatinine in mouse 24 hours urinary samples 
1.1. Chemicals and reagents 
Acetonitrile and formic acid at UHPLC-grade were purchased from Biosolve (Dieuze, France) or 
Sigma-Aldrich (St. Louis, MO). Distilled water was obtained using a MilliQ water purification 
system (Millipore, USA). Corticosterone-D8 (98% isotopic purity) was purchased from C/D/N 
Isotopes Inc (Pointe-Claire, Canada). Creatinine, corticosterone, 11-dehydrocorticosterone, 5α -
dihydrocorticosterone (5α-DHB), creatinine-D3 (99.9% isotopic purity) and all other chemicals 
were obtained from Sigma-Aldrich (St. Louis, MO) of the highest grade available. 
1.2. Instrumentation and analytical conditions 
Solid phase extraction: Extraction was performed by use of a vacuum manifold (Agilent 
Technologies, California, USA) equipped with Oasis HBL SPE cartridges (60 mg, Waters, 
Massachusetts; USA). Samples were evaporated to dryness using a Genevac EZ-2 plus 
centrifugal vacuum evaporator (Genevac, Suffolk, UK). 
Analytical instruments: Ultra-High performance liquid chromatography-tandem mass 
spectrometry (UHPLC-MS/MS) using an Agilent 1290 UHPLC instrument equipped with a binary 
solvent delivery system, an auto sampler (at 4 °C), and a column oven, coupled to an Agilent 
6490 triple quadrupole mass spectrometer equipped with a jet stream electrospray ionization 
interface (AJS-ESI) (Agilent Technologies, Basel, Switzerland) was used for steroids and 
creatinine quantification.  
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Liquid chromatography: The chromatographic separation was performed on a Waters Acquity 
UPLC BEH C18, 1.7 µm, 2.1×150 mm, column (Waters, Wexford, Ireland) at column 
temperature of 50 ± 0.8 ºC for creatinine and 54 ± 0.8 ºC for steroids. The mobile phase was 
water-acetonitrile-formic acid (80/20/0.1; v/v/v) with a constant flow rate of 0.6 mL/min for 
creatinine and water-acetonitrile-formic acid (70/30/0.1; v/v/v) with flow rate of 0.5 mL/min for 
steroids respectively. Creatinine was separated within 2 min, followed by 1 min column wash at 
100 % acetonitrile and subsequent column re-equilibration for 1 min. Steroids were separated 
with 30 % of mobile phase B at a ramping flow rate from 0.5 ml/min to 0.2 ml/min within 0 - 4.8 
min, followed by separation at constant flow rate of 0.2 mL/min using a gradient of B (30 – 10%) 
during 4.8-7 min and 7.5-13 min at 30 % of mobile phase B. Separation was followed by column 
wash (100% of mobile phase B, 0.5 mL/min) at 15 min onwards and the run was stopped after 
18 min, followed by re-equilibration of the column for 3 min. A methanol in water (75/25 v/v) 
mixture was used as needle and needle-seat flushing solvent for 10 s after sample injection. 
Samples were stored until analysis in the auto sampler (maintained at 4 °C). The injection 
volume was 1 µL per creatinine sample and 5 µL for steroids respectively.  
 
Mass spectrometry: Characteristic precursor ions and their corresponding product ions for 
multiple reaction monitoring (MRM) were defined by use of the compound optimizer software 
module included within the Mass Hunter Workstation software (Agilent Technologies, California, 
USA). Analytes were quantified using the corresponding mass transitions: Creatinine: m/z 
114.07→44.1 (29 V, Dwell 100 ms) and m/z 114.0742.1 (40 V, Dwell 200 ms); creatinine-D3 
117.07→47.1 (29 V, Dwell 100 ms) and m/z 117.0745.1 (29 V, Dwell 200 ms); corticosterone 
m/z 347.2→329.2 (9 V, Dwell 150 ms) and m/z 347.2→121.1 (21 V, Dwell 200 ms); 
corticosterone-D8 m/z 355.2→125.1 (25 V, Dwell 100 ms); 11-dehydrocorticosterone m/z 
345.2→121.1 (21 V, Dwell 300 ms) and m/z 345.2→90.9 (60 V, Dwell 200 ms) and 5α-DHB m/z 
349.2→313 (13 V, Dwell 150 ms) and m/z 349.2→104.9 (41 V, Dwell 200 ms). The AJS-ESI 
source conditions were optimized using the integrated source optimizer tool and set in the 
positive ion mode as following: Nitrogen gas temperature (290 °C), gas flow (14 l/min), nebulizer 
(20 psi), sheath gas temperature (350 °C), sheath gas flow (11 l/min), capillary voltage (4000 V), 
and nozzle voltage (1500 V). (Agilent Technologies, California, USA, B.08.00/Build 8.0.8023.0).  
Data analysis: The MassHunter Workstation Acquisition software Version B.08.00/Build 
8.0.8023.0 and MassHunter Workstation Software Quantitative Analysis Version B.07.01 /Build 
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7.1.524.0, respectively (Agilent Technologies, California, USA) was used for data acquisition 
and subsequent data analysis. 
Sample preparation: Mouse urine samples were centrifuged at 16.1 x g for 30 min at 4°C. To 
500 μl of urinary supernatant or calibrator an internal standard solution containing 
corticosterone-D8 and creatinine-D3 (100 µg/ml) was added and samples were diluted to a final 
volume of 1.9 mL with sodium acetate buffer (100 mM, pH 4.3). To each urine sample ß-
Glucuronidase from Helix promatia (10 000 units/mL) were added and samples were incubated 
in a thermoshaker thorough shaking (2 hrs, 900 rpm, 55 °C). Samples were centrifuged (10 min, 
16,000 × rcf, 4 °C). For solid phase extraction supernatant of each sample or calibrator (1800 
µL) was transferred to Oasis HBL SPE cartridges (preconditioned with methanol and water, 3 
mL each). Samples were washed with water (3x1 mL), water/methanol (3x1 mL, 90/10 v/v) and 
water-methanol-ammonia (1 mL, 60/40/2; v/v/v). Samples were allowed to dry under full vacuum 
for 5 minutes and eluted with methanol (3x 500 µL). Samples were evaporated to dryness and 
reconstituted in 25 µL methanol (10 min, 1300 rpm, 4 °C, thermoshaker). 
Chromatographic performance: Ten-point calibration curves over the range of 0.002 to 0.6 
mmol/L for creatinine and 1.9 to 500 nmol/L for corticosterone, 11-dehydro-corticosterone and 
5alpha-dihydro-corticosterone were generated by a zero sample and nine calibrators in 
phosphate buffered saline. The coefficient of determination (R2) was 0.99 and at least 75% of all 
calibrators had to be valid. 
 
